Jounce Therapeutics (JNCE) PT Lowered to $12.00 at Raymond James

Jounce Therapeutics (NASDAQ:JNCE) had its target price lowered by Raymond James from $13.00 to $12.00 in a research note issued to investors on Tuesday morning. The brokerage currently has an outperform rating on the stock.

JNCE has been the topic of a number of other research reports. Zacks Investment Research lowered Jounce Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 15th. HC Wainwright set a $13.00 price target on Jounce Therapeutics and gave the stock a buy rating in a research report on Monday, August 13th. Cowen reaffirmed a hold rating on shares of Jounce Therapeutics in a research report on Thursday, August 9th. JPMorgan Chase & Co. dropped their price target on Jounce Therapeutics from $12.00 to $10.00 and set a hold rating on the stock in a research report on Friday, August 10th. Finally, ValuEngine raised Jounce Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 2nd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $11.92.

Shares of NASDAQ JNCE traded down $0.32 during mid-day trading on Tuesday, reaching $4.53. 47,368 shares of the company’s stock were exchanged, compared to its average volume of 465,875. The firm has a market cap of $174.88 million, a P/E ratio of -7.95 and a beta of 5.33. Jounce Therapeutics has a twelve month low of $4.50 and a twelve month high of $29.25.



Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Friday, August 10th. The company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.23. The company had revenue of $19.38 million for the quarter, compared to analyst estimates of $12.47 million. Jounce Therapeutics had a negative return on equity of 23.27% and a negative net margin of 50.54%. As a group, analysts anticipate that Jounce Therapeutics will post -1.26 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the stock. NumerixS Investment Technologies Inc bought a new position in shares of Jounce Therapeutics during the second quarter worth about $132,000. Creative Planning bought a new position in shares of Jounce Therapeutics during the third quarter worth about $143,000. MetLife Investment Advisors LLC bought a new position in shares of Jounce Therapeutics during the first quarter worth about $159,000. Bank of America Corp DE grew its holdings in shares of Jounce Therapeutics by 243.4% during the second quarter. Bank of America Corp DE now owns 28,607 shares of the company’s stock worth $219,000 after buying an additional 20,276 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Jounce Therapeutics during the first quarter worth about $243,000. Institutional investors and hedge funds own 84.11% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Further Reading: Bear Market

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply